These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 25823819)

  • 1. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.
    Bill A; Gutierrez A; Kulkarni S; Kemp C; Bonenfant D; Voshol H; Duvvuri U; Gaither LA
    Oncotarget; 2015 Apr; 6(11):9173-88. PubMed ID: 25823819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMEM16A/ANO1 suppression improves response to antibody-mediated targeted therapy of EGFR and HER2/ERBB2.
    Kulkarni S; Bill A; Godse NR; Khan NI; Kass JI; Steehler K; Kemp C; Davis K; Bertrand CA; Vyas AR; Holt DE; Grandis JR; Gaither LA; Duvvuri U
    Genes Chromosomes Cancer; 2017 Jun; 56(6):460-471. PubMed ID: 28177558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced expression of ANO1 in head and neck squamous cell carcinoma causes cell migration and correlates with poor prognosis.
    Ruiz C; Martins JR; Rudin F; Schneider S; Dietsche T; Fischer CA; Tornillo L; Terracciano LM; Schreiber R; Bubendorf L; Kunzelmann K
    PLoS One; 2012; 7(8):e43265. PubMed ID: 22912841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
    Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
    Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
    Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of Anoctamin-1 gene at 11q13 in the development and progression of head and neck squamous cell carcinomas.
    Rodrigo JP; Menéndez ST; Hermida-Prado F; Álvarez-Teijeiro S; Villaronga MÁ; Alonso-Durán L; Vallina A; Martínez-Camblor P; Astudillo A; Suárez C; María García-Pedrero J
    Sci Rep; 2015 Oct; 5():15698. PubMed ID: 26498851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
    Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling.
    Britschgi A; Bill A; Brinkhaus H; Rothwell C; Clay I; Duss S; Rebhan M; Raman P; Guy CT; Wetzel K; George E; Popa MO; Lilley S; Choudhury H; Gosling M; Wang L; Fitzgerald S; Borawski J; Baffoe J; Labow M; Gaither LA; Bentires-Alj M
    Proc Natl Acad Sci U S A; 2013 Mar; 110(11):E1026-34. PubMed ID: 23431153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells.
    Sebastian S; Azzariti A; Accardi R; Conti D; Pilato B; LaCalamita R; Porcelli L; Simone GM; Tommasi S; Tommasino M; Paradiso A
    Int J Mol Med; 2008 Jun; 21(6):809-17. PubMed ID: 18506376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of stable ANO1 overexpression on biological behaviors of human laryngeal squamous cell carcinoma Hep-2 cells in vitro].
    Li Y; Zhang J; Yang K; Zhang F; Chen R; Chen D
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Feb; 34(2):251-5. PubMed ID: 24589607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.
    Pernas FG; Allen CT; Winters ME; Yan B; Friedman J; Dabir B; Saigal K; Mundinger GS; Xu X; Morris JC; Calvo KR; Van Waes C; Chen Z
    Clin Cancer Res; 2009 Apr; 15(7):2361-72. PubMed ID: 19318490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
    Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
    Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
    Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
    Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ANO1 amplification and expression in HNSCC with a high propensity for future distant metastasis and its functions in HNSCC cell lines.
    Ayoub C; Wasylyk C; Li Y; Thomas E; Marisa L; Robé A; Roux M; Abecassis J; de Reyniès A; Wasylyk B
    Br J Cancer; 2010 Aug; 103(5):715-26. PubMed ID: 20664600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines.
    Hinz TK; Kleczko EK; Singleton KR; Calhoun J; Marek LA; Kim J; Tan AC; Heasley LE
    Mol Pharmacol; 2019 Dec; 96(6):862-870. PubMed ID: 31554698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMEM16A/ANO1 is differentially expressed in HPV-negative versus HPV-positive head and neck squamous cell carcinoma through promoter methylation.
    Dixit R; Kemp C; Kulich S; Seethala R; Chiosea S; Ling S; Ha PK; Duvvuri U
    Sci Rep; 2015 Nov; 5():16657. PubMed ID: 26563938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.